Search

Search Constraints

You searched for: Author/Creator Ukropec, Jon

Search Results

1. A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC). (March 2019)

2. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Issue 6 (June 2021)

3. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. (3rd March 2019)

4. Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Issue 6 (17th July 2020)

5. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Issue 10 (1st April 2021)

6. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Issue 10218 (11th January 2020)

7. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Issue 22 (5th November 2018)